JSC Avexima is a Russian full-cycle pharmaceutical company. Its main activities are the synthesis of active pharmaceutical substances (APIs), along with the development, production, and promotion of modern medicines.
We do everything possible to ensure that people get sick as little as possible and recover as quickly, live full lives, and enjoy every day of them.
We continuously improve all stages of drug development, implementing new approaches, building constructive business processes, and modernizing pharmaceutical production to create in-demand medicines.
Every step - from development to manufacturing of medicines - is under strict control, allowing us to guarantee the safety and effectiveness of the product. We are fully aware of our responsibility and bear it with pride.
2011
The company Avexima was established, subsequently taking over the management of pharmaceutical plants in the Sverdlovsk and Kemerovo regions. As a result, the company's portfolio was expanded with more than 100 drugs across various therapeutic areas.
2011
Large-scale reconstruction and modernization of the chemical pharmaceutical plant in Anzhero-Sudzhensk (Kemerovo region). The enterprise was renamed Avexima Siberia LLC.
2013
Large-scale reconstruction and modernization of the Irbit Chemical Pharmaceutical Plant in Irbit (Sverdlovsk region). The enterprise was renamed Irbit Chemical Pharmaceutical Plant JSC.
2018
Acquisition of Immafarma, a production asset for modern immunological drugs.
2020
Opening of the Avexima R&D center in the Skolkovo Technopark.
2020
The Avexima Research Center, which is currently one of the largest scientific centers in Skolkovo, is starting work.
2021
Signing of an agreement with the Moscow Region Development Corporation JSC on the expansion of cooperation for the construction of a pharmaceutical cluster in the Yesipovo Industrial Park, Moscow Region.
2022
Completion of the approval procedure for the design documentation for the construction of the Yesipovo pharmaceutical production and logistics complex.
2023
Expansion of the export operations. Our products gained the trust of new markets, strengthening the brand's global presence and confirming the company's status as a reliable international player.
2024
Expansion of the product portfolio of innovative medicines, generics (OTC, Rx), and dietary supplements.
2025
Strategic modernization of production facilities strengthened our competitive advantages and laid the foundation for future growth.
Dear Colleagues and Partners,
Our company is one of the leading manufacturers not only of innovative drugs but also of well-established, effective, affordable, high-quality medicines for treating various diseases.
Today, the company's portfolio includes more than 120 medicinal products, many of which are included in the Vital and Essential Drugs (VED) list. The production division of Avexima includes several modern pharmaceutical plants:
Thanks to its own production base, Avexima is one of the few unique pharmaceutical manufacturers, since it not only produces finished dosage forms but also synthesizes their basis - the active pharmaceutical ingredient (API). The entire drug manufacturing process undergoes rigorous quality control in modern laboratory facilities equipped at all of the company's plants.
Avexima is actively developing in the direction of new drug development. The modern Avexima R&D center in the Skolkovo Technopark is one of the most advanced research centers in the country.
This allows us not only to improve the quality and enhance the effectiveness of the company's existing products but also to create new drugs for treating today's most pressing health challenges.
Modern production, the advancement of scientific research in pharmacology, and the high professionalism of our employees enable us to create modern, high-quality, and affordable medicines for consumers and to strengthen the foundation of the country's pharmaceutical security.
General Director
Leveraging a robust scientific foundation, extensive experience, and expertise in the production of active pharmaceutical ingredients (APIs) and the manufacture of various drug dosage forms, as well as a successful track record in promotion and existing contracts with major distributors and pharmacy chains, Avexima offers partnership opportunities in contract manufacturing and comprehensive services for the market entry and commercialization of partner companies products.
*Available with a long-term contract.
As part of the collaboration, the company's specialists in production, promotion, and marketing will develop an optimal program for the market entry and promotion of the partner company's products, tailored to the partner's capabilities and expected revenue indicators.